Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

3.560 +0.150 (+4.40%)

Streaming Delayed Price Updated: 11:10 AM EDT, Jul 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	326,792
Open	3.360
Bid (Size)	3.550 (1,100)
Ask (Size)	3.560 (300)
Prev. Close	3.410
Today's Range	3.250 - 3.560
52wk Range	2.710 - 7.340
Shares Outstanding	348,875,959
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

July 06, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

June 25, 2026

From Agenus Inc.

Via Business Wire

Performance

YTD	+10.2%	+10.2%
1 Month	+13.4%	+13.4%
3 Month	-5.6%	-5.6%
6 Month	+10.6%	+10.6%
1 Year	-31.3%	-31.3%

More News

Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves ↗

June 16, 2026

Via MarketBeat

Agenus Announces Virtual 2026 Annual Shareholders Meeting

June 02, 2026

From Agenus Inc.

Via Business Wire

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

May 21, 2026

From Agenus Inc.

Via Business Wire

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

May 21, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

May 15, 2026

From Agenus Inc.

Via Business Wire

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

May 11, 2026

From Agenus Inc.

Via Business Wire

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

May 04, 2026

From Agenus Bio

Via Business Wire

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

April 21, 2026

From Agenus Inc.

Via Business Wire

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

April 21, 2026

From Agenus Inc. & BAP Pharma

Via Business Wire

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

April 17, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

April 03, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

April 01, 2026

From Agenus Inc.

Via Business Wire

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

March 26, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

March 17, 2026

From Agenus Bio

Via Business Wire

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

March 16, 2026

From Agenus Inc.

Via Business Wire

Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

March 10, 2026

From Agenus Inc.

Via Business Wire

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

March 04, 2026

From Agenus Bio

Via Business Wire

Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

February 19, 2026

From Agenus Bio

Via Business Wire

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

February 09, 2026

From Agenus Bio

Via Business Wire

Agenus (AGEN) Q2 2025 Earnings Call Transcript ↗

January 27, 2026

Via The Motley Fool

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

January 21, 2026

From Agenus Inc.

Via Business Wire

Agenus to Host First 2026 Stakeholder Webcast

January 20, 2026

From Agenus Inc.

Via Business Wire

Thursday's session: top gainers and losers ↗

January 15, 2026

Via Chartmill

Frequently Asked Questions

Is Agenus Inc. - Common Stock publicly traded?

Yes, Agenus Inc. - Common Stock is publicly traded.

What exchange does Agenus Inc. - Common Stock trade on?

Agenus Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Agenus Inc. - Common Stock?

The ticker symbol for Agenus Inc. - Common Stock is AGEN on the Nasdaq Stock Market

What is the current price of Agenus Inc. - Common Stock?

The current price of Agenus Inc. - Common Stock is 3.560

When was Agenus Inc. - Common Stock last traded?

The last trade of Agenus Inc. - Common Stock was at 07/07/26 11:10 AM ET

What is the market capitalization of Agenus Inc. - Common Stock?

The market capitalization of Agenus Inc. - Common Stock is 1.24B

How many shares of Agenus Inc. - Common Stock are outstanding?

Agenus Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.